A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification

NCT02100475 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes
Diabetes Mellitus, Type 2

Interventions

DRUG: insulin degludec/liraglutide
DRUG: insulin aspart

Sponsor

Novo Nordisk A/S